Abstract 1205P
Background
The probability of discovering mutation-based therapy through comprehensive genomic profiling (CGP) remains low. To enhance the effectiveness and efficiency of precision medicine, it is crucial to identify patients who are likely to benefit from CGP tests. This study aimed to identify characteristics of patients in which mutation-based treatments are discovered by CGP tests.
Methods
We retrospectively analyzed data from 60,655 patients registered in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, which covers 99.7% of cancer patients who have undergone CGP tests in Japan. We developed an eXtreme Gradient Boosting (XGBoost) machine learning model, and used clinical information as input to predict the likelihood of discovering mutation-based drugs through CGP tests. SHapley Additive exPlanations (SHAP) was employed to extract significant features contributing to the model prediction.
Results
The prediction model achieved an area under the receiver operating characteristic curve of 0.819 for the overall cancer population. Positive SHAP values were observed for patients with breast (mean SHAP in breast cancer patients: 1.66), lung (1.19), prostate (0.81), and colorectal (0.17) cancers, while negative SHAP values were associated with pancreatic (-2.40), brain (-1.37), and biliary tract (-0.44) cancers. Positive SHAP values were also associated with the presence of distant metastases and advanced age. Similar trends were observed in cancer type-specific prediction models. Distant metastasis was also associated with discovery of mutation-based therapy in the breast cancer-specific model, even after excluding liquid CGP data. In the adolescent and young adult (AYA) group, brain and bone tumors were associated with negative SHAP values.
Conclusions
Our analysis identified features that predict cases in which mutation-based treatments are discovered by CGP tests, both in the overall cancer population and within specific cancer types and the AYA group. Expedited CGP testing is recommended for patients who match the identified profile to facilitate early targeted therapy interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Watanabe, H. Kage: Financial Interests, Institutional, Research Funding: Konica Minolta. K. Oda: Financial Interests, Personal, Advisory Role: Chugai Pharma, Takeda, AstraZeneca/Merck, AstraZeneca, Konica Minolta; Financial Interests, Institutional, Research Funding: AstraZeneca/Merck, Konica Minolta. All other authors have declared no conflicts of interest.
Resources from the same session
1492P - The role of LACE index in predicting 30-day unplanned readmission in patients receiving immunotherapy
Presenter: Duygu Ercan Uzundal
Session: Poster session 10
1493P - The Italian version of the FAMCARE-P13 questionnaire: A validation study
Presenter: Giacomo Massa
Session: Poster session 10
1494P - Prognostic features in NSCLC patients with ECOG-PS 2-4: A prospective cohort study
Presenter: Gilberto De Castro Jr.
Session: Poster session 10
1495P - Impact of social isolation on the clinical outcomes in advanced NSCLC patients
Presenter: Yoh Yamaguchi
Session: Poster session 10
1496P - Predictors of early mortality after hemodialysis in patients with cancer and acute kidney injury
Presenter: Suleyman Cagin Gurbuz
Session: Poster session 10
1497P - Resuscitation decisions in advanced cancer: A mixed methods study exploring survival outcomes and views of healthcare professionals
Presenter: Rachel Prichard
Session: Poster session 10
1498P - Acute myeloid leukemia: Trends in palliative care utilization in hospitalized patients over 65 years old - A national inpatient sample study (2016-2020)
Presenter: Marco Bermudez
Session: Poster session 10
Resources:
Abstract
1499P - Knowledge, attitudes, and current practices toward lung cancer palliative care management in China: A national survey
Presenter: Mengting Chen
Session: Poster session 10
Resources:
Abstract
1500P - Caring for carers: The impact of death & dying on doctors-in-training in an Irish tertiary referral hospital
Presenter: Conor Moloney
Session: Poster session 10
1501P - Sex-specific variation in symptoms presentation: Experience of an outpatient clinic integrated model between radiotherapy and palliative care
Presenter: Luca Tontini
Session: Poster session 10